Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline
Identifieur interne : 003455 ( Main/Exploration ); précédent : 003454; suivant : 003456Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline
Auteurs : J. Antonelle Demarcaida [États-Unis] ; Steven R. Schwid [États-Unis] ; William B. White [États-Unis] ; Karen Blindauer [États-Unis] ; Stanley Fahn [États-Unis] ; Karl Kieburtz [États-Unis] ; Matthew Stern [États-Unis] ; Ira Shoulson [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-10.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Administration, Oral, Aged, Amine oxidase (flavin-containing), Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Blood Pressure (drug effects), Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Food-Drug Interactions, Heart Rate (drug effects), Human, Humans, Indans (administration & dosage), Indans (adverse effects), Levodopa (administration & dosage), Levodopa (adverse effects), MAO B inhibitor, Male, Middle Aged, Monoamine Oxidase Inhibitors (administration & dosage), Monoamine Oxidase Inhibitors (adverse effects), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Rasagiline, Risk Factors, Treatment, Tyramine, Tyramine (administration & dosage), Tyramine (diagnostic use), monoamine oxidase inhibitor, pressor response, rasagiline, tolerability, tyramine.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Indans, Levodopa, Monoamine Oxidase Inhibitors, Tyramine.
- chemical , adverse effects : Antiparkinson Agents, Indans, Levodopa, Monoamine Oxidase Inhibitors.
- chemical , diagnostic use : Tyramine.
- drug effects : Blood Pressure, Heart Rate.
- drug therapy : Parkinson Disease.
- Administration, Oral, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Food-Drug Interactions, Humans, Male, Middle Aged, Risk Factors.
Abstract
Rasagiline is a novel, potent, and selective MAO‐B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50–75 mg) were performed in 72 rasagiline‐treated and 38 placebo‐treated Parkinson's disease (PD) patients at the end of two double‐blind placebo‐controlled trials of rasagiline. An abnormal pressor response was prespecified as three consecutive measurements of systolic blood pressure (BP) increases of ≥ 30 mm Hg and/or bradycardia of < 40 beats/min. In the first study involving 55 patients with early PD on rasagiline monotherapy, no patients randomized to rasagiline (1 mg/2 mg; n = 38) or placebo (n = 17) developed systolic BP (SBP) or heart rate changes indicative of a tyramine reaction. In the second trial involving 55 levodopa‐treated patients, 3 of 22 subjects on rasagiline 0.5 mg/day and 1 of 21 subjects on placebo developed asymptomatic, self‐limiting SBP elevations ≥ 30 mm Hg on three measurements. No subject on 1 mg/day rasagiline (0/12) experienced significant BP or heart rate changes following tyramine ingestion. These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21048
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B97
- to stream Istex, to step Curation: 001B97
- to stream Istex, to step Checkpoint: 001F15
- to stream PubMed, to step Corpus: 002B45
- to stream PubMed, to step Curation: 002B45
- to stream PubMed, to step Checkpoint: 002D46
- to stream Ncbi, to step Merge: 001793
- to stream Ncbi, to step Curation: 001793
- to stream Ncbi, to step Checkpoint: 001793
- to stream Main, to step Merge: 004769
- to stream PascalFrancis, to step Corpus: 001950
- to stream PascalFrancis, to step Curation: 001371
- to stream PascalFrancis, to step Checkpoint: 001B16
- to stream Main, to step Merge: 004C11
- to stream Main, to step Curation: 003455
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline</title><author><name sortKey="Demarcaida, J Antonelle" sort="Demarcaida, J Antonelle" uniqKey="Demarcaida J" first="J. Antonelle" last="Demarcaida">J. Antonelle Demarcaida</name></author><author><name sortKey="Schwid, Steven R" sort="Schwid, Steven R" uniqKey="Schwid S" first="Steven R." last="Schwid">Steven R. Schwid</name></author><author><name sortKey="White, William B" sort="White, William B" uniqKey="White W" first="William B." last="White">William B. White</name></author><author><name sortKey="Blindauer, Karen" sort="Blindauer, Karen" uniqKey="Blindauer K" first="Karen" last="Blindauer">Karen Blindauer</name></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2A726F2D49EC2CE7F8DFE86AE8FEF1CAB2E0FC7D</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21048</idno><idno type="url">https://api.istex.fr/document/2A726F2D49EC2CE7F8DFE86AE8FEF1CAB2E0FC7D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B97</idno><idno type="wicri:Area/Istex/Curation">001B97</idno><idno type="wicri:Area/Istex/Checkpoint">001F15</idno><idno type="wicri:doubleKey">0885-3185:2006:Demarcaida J:effects:of:tyramine</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16856145</idno><idno type="wicri:Area/PubMed/Corpus">002B45</idno><idno type="wicri:Area/PubMed/Curation">002B45</idno><idno type="wicri:Area/PubMed/Checkpoint">002D46</idno><idno type="wicri:Area/Ncbi/Merge">001793</idno><idno type="wicri:Area/Ncbi/Curation">001793</idno><idno type="wicri:Area/Ncbi/Checkpoint">001793</idno><idno type="wicri:doubleKey">0885-3185:2006:Demarcaida J:effects:of:tyramine</idno><idno type="wicri:Area/Main/Merge">004769</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0538592</idno><idno type="wicri:Area/PascalFrancis/Corpus">001950</idno><idno type="wicri:Area/PascalFrancis/Curation">001371</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001B16</idno><idno type="wicri:doubleKey">0885-3185:2006:Demarcaida J:effects:of:tyramine</idno><idno type="wicri:Area/Main/Merge">004C11</idno><idno type="wicri:Area/Main/Curation">003455</idno><idno type="wicri:Area/Main/Exploration">003455</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline</title><author><name sortKey="Demarcaida, J Antonelle" sort="Demarcaida, J Antonelle" uniqKey="Demarcaida J" first="J. Antonelle" last="Demarcaida">J. Antonelle Demarcaida</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Connecticut, Farmington, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Schwid, Steven R" sort="Schwid, Steven R" uniqKey="Schwid S" first="Steven R." last="Schwid">Steven R. Schwid</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="White, William B" sort="White, William B" uniqKey="White W" first="William B." last="White">William B. White</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Connecticut, Farmington, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Blindauer, Karen" sort="Blindauer, Karen" uniqKey="Blindauer K" first="Karen" last="Blindauer">Karen Blindauer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neurological Institute, Columbia University Medical Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Penn Neurological Institute, Philadelphia, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-10">2006-10</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1716">1716</biblScope><biblScope unit="page" to="1721">1721</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2A726F2D49EC2CE7F8DFE86AE8FEF1CAB2E0FC7D</idno><idno type="DOI">10.1002/mds.21048</idno><idno type="ArticleID">MDS21048</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Amine oxidase (flavin-containing)</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Blood Pressure (drug effects)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Food-Drug Interactions</term><term>Heart Rate (drug effects)</term><term>Human</term><term>Humans</term><term>Indans (administration & dosage)</term><term>Indans (adverse effects)</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>MAO B inhibitor</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase Inhibitors (administration & dosage)</term><term>Monoamine Oxidase Inhibitors (adverse effects)</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Rasagiline</term><term>Risk Factors</term><term>Treatment</term><term>Tyramine</term><term>Tyramine (administration & dosage)</term><term>Tyramine (diagnostic use)</term><term>monoamine oxidase inhibitor</term><term>pressor response</term><term>rasagiline</term><term>tolerability</term><term>tyramine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Indans</term><term>Levodopa</term><term>Monoamine Oxidase Inhibitors</term><term>Tyramine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Indans</term><term>Levodopa</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Tyramine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Pressure</term><term>Heart Rate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Food-Drug Interactions</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Amine oxidase (flavin-containing)</term><term>Homme</term><term>IMAO B</term><term>Parkinson maladie</term><term>Rasagiline</term><term>Système nerveux pathologie</term><term>Traitement</term><term>Tyramine</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rasagiline is a novel, potent, and selective MAO‐B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50–75 mg) were performed in 72 rasagiline‐treated and 38 placebo‐treated Parkinson's disease (PD) patients at the end of two double‐blind placebo‐controlled trials of rasagiline. An abnormal pressor response was prespecified as three consecutive measurements of systolic blood pressure (BP) increases of ≥ 30 mm Hg and/or bradycardia of < 40 beats/min. In the first study involving 55 patients with early PD on rasagiline monotherapy, no patients randomized to rasagiline (1 mg/2 mg; n = 38) or placebo (n = 17) developed systolic BP (SBP) or heart rate changes indicative of a tyramine reaction. In the second trial involving 55 levodopa‐treated patients, 3 of 22 subjects on rasagiline 0.5 mg/day and 1 of 21 subjects on placebo developed asymptomatic, self‐limiting SBP elevations ≥ 30 mm Hg on three measurements. No subject on 1 mg/day rasagiline (0/12) experienced significant BP or heart rate changes following tyramine ingestion. These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Connecticut</li><li>Pennsylvanie</li><li>Wisconsin</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Connecticut"><name sortKey="Demarcaida, J Antonelle" sort="Demarcaida, J Antonelle" uniqKey="Demarcaida J" first="J. Antonelle" last="Demarcaida">J. Antonelle Demarcaida</name></region><name sortKey="Blindauer, Karen" sort="Blindauer, Karen" uniqKey="Blindauer K" first="Karen" last="Blindauer">Karen Blindauer</name><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><name sortKey="Schwid, Steven R" sort="Schwid, Steven R" uniqKey="Schwid S" first="Steven R." last="Schwid">Steven R. Schwid</name><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name><name sortKey="White, William B" sort="White, William B" uniqKey="White W" first="William B." last="White">William B. White</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003455 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003455 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2A726F2D49EC2CE7F8DFE86AE8FEF1CAB2E0FC7D
|texte= Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline
}}
| This area was generated with Dilib version V0.6.23. |  |